Brainchip Holdings Ltd. · ASX:BRN
Brainchip — Investor Presentation (July 2024)
10 slides from Brainchip's investor presentation, Jul 25, 2024
Slide 1: Fully Underwritten Institutional Placement, Existing Share Sale & Share Purchase Plan
For personal use only Fully Underwritten Institutional Placement, Existing Share Sale & Share Purchase Plan to raise up to A$25 Million July 2024
Slide 2: Equity Raise Overview
Equity Raise Overview Size and structure A fully underwritten ~$22.0 million capital raising comprising: o A ~$20.0 million placement via the issue of approximately 103.2 million new shares equating to ~5.6% of existing BrainChip shares on issue, falling within the Company’s existing placement cap
Slide 3: Placement and SPP Timeline
Placement and SPP Timeline Event Date For personal use only Trading halt Tuesday, 23 July 2024 Bookbuild opens Tuesday, 23 July 2024 Bookbuild closes 9:00am AEST Wednesday, 24 July 2024 SPP record date 7:00pm AEST Wednesday, 24 July 2024 Announcement of transaction completion Thursday, 25 July 2024
Slide 4: Sources of Funds & Balance Sheet
Sources of Funds & Balance Sheet Pro-forma Balance Sheet (unaudited)1,2,3 Sources A$M Placement 20.0 30 June ’24 Adjustment Pro-forma For personal use only Existing Share Sale 2.0 US$M US$M US$M SPP 3.0 Assets Total 25.0 Cash 10.9 20.4 31.3 Other Current 5.6 (3.6) 2.0 Uses A$M Non-current 2.4 - 2.4
Slide 5: Use of Funds
Use of Funds Proceeds from the Placement and SPP will be used primarily to support the ongoing commercialisation of Akida 2.0 For personal use only technology and the development, productization and commercialization of the new TENNs product. This represents the next expansion in BrainChip’s product
Slide 6: Key Risks
KEY RISKS There are a number of factors, specific to an investment in BrainChip, specific to the Material Contract and of a general nature, which may affect the future operating and financial performance of BrainChip and the industry in which it operates and the outcome of an investment in BrainChip
Slide 7: Key Risks
KEY RISKS Reputational damage Issues of a varying nature may arise that would give rise to reputational risk and cause harm to BrainChip’s business dealings and prospects. Failure to address these potential issues appropriately could give rise to additional legal risk, subject entities within the Gr
Slide 8: Key Risks
KEY RISKS Liquidity The Group’s Shares are only listed on the ASX and will not be listed for trading on any other securities exchanges. There can be no guarantee that an active market in the Shares will develop or continue. If an active market for the Shares does not develop or is not sustained, it
Slide 9: International Offer Restrictions
INTERNATIONAL OFFER RESTRICTIONS This document does not constitute an offer of new ordinary shares (“New Shares”) of the Company in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be offered or sold, in any
Slide 10: International Offer Restrictions
INTERNATIONAL OFFER RESTRICTIONS United States This document and any other materials relating to the Entitlement Offer and the Entitlement and Acceptance Form do not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or to any person who is acting
BrainChip Holdings — Investor Presentation (July 2024) on 6ix